The Peripheral Season 1 - Episode 7 __EXCLUSIVE__
Based on the novel by William Gibson, this adaptation is being managed by Westworld creators Lisa Joy and Jonathan Nolan, who were recently dealt a blow when their mega-budget HBO series was axed after four seasons.
The Peripheral Season 1 - Episode 7
However, in a nod to Westworld's many earth-shattering twists and turns, The Peripheral star Charlotte Riley said there's no guarantee any of the cast would return for season 2, as the plot could go in an entirely different direction.
Prime Video ordered an eight-episode season for the new series. The first episode premiered Friday, Oct. 21. The streaming service has set a weekly schedule, with one new installment released weekly through Dec. 9. Here is a full breakdown:
From the very first episode, the Research Institute (from future London in 2099, around 70 years ahead of Flynne's time) had a hit put on Flynne simply because she'd seen too much, thanks to the little "SIM" game the mysterious Aleita setup. She was chased down by the mercenary bounty hunters, Clanton County's local drug baron Corbell Pickett and retired killer Bob. She successfully left them all in the dust, yet Dr. Cherise Nuland, a prominent figure at the Research Institute, is relentless and finally plans to blow up a silo in Flynne's county that would assuredly wipe her and everyone she loves out.
That end stitch is where things become Westworld-level tricky. Because of the show's editing, it looks like the consciousness of the dead Flynne has been transferred to Flynne's peripheral (the future robot body accessed via the special headset). However, the past Flynne died without wearing a headset. The way this is possible might be that, because Flynne created a new base stub, she was only a pilot in her old body. When it died, she returned to her new stub, then from there, still wearing the headset, she could jump into her future peripheral. Good luck deciphering all that!
The Research Institute is intent on eliminating Flynne because of something to do with bacteria inside her brain. That whole "SIM" ultra-realistic game sequence in episode 1, where Flynne pilots her brother Burton's peripheral (the robot the headset connects to), turned out to be all part of Aleita's plan to steal and hide "the entire library" of files from the Research Institute. Aleita thought she could download the stolen files into Burton's haptic implants, storing them in the past timeline where they would be untraceable. Because Flynne doesn't have implants, the headset "translated the data into bacterial DNA," according to Ash. This data then began to "colonize" her brain. (That explains all the seizures Flynne was having.)
What data exactly? Data on something called a "neural adjustment mechanism," which sounds like a mind control doodad. In episode 5, Research Institute worker Grace naively reveals to Aleita that they're behind the haptic implants embedded in US soldiers in the stub, including Burton and Connor. These implants can "subtly goose" the subject's "neural chemistry" in the "compassion center" of the brain. The Research Institute thinks that, with this technology, it can prevent mob violence and influence society on a grander level. Grace lets slip they're already implementing some of these changes.
In episode 7, Inspector Lowbeer lets Flynne in on the Metropolitan Police's intriguing intel. She reveals that Connor didn't lose his limbs in the Texas War in the original timeline, before Flynne's stub was created. The haptic technology he and Flynne's brother Burton are integrated with hadn't been developed for another couple of decades. In this original timeline, Burton -- fighting as a common soldier instead of an enhanced one -- was killed, while Connor survived unscathed.
He's rich, Russian and sports an impressive goatee, so he must be a bad guy, right? Yet early in the season, Zubov had been positioned as more of a good guy, working on the same side as his kind friend Wilf. Yet tensions soon begin to simmer in the Zubov compound until Ash reveals Zubov is a "killer." Flynne learns from Wilf that Zubov is interested in cloning -- another red flag -- and Zubov begins to both lie to Wilf and dodge his questions, including one about what Zubov's motivations and goals truly are. "Take some care of what you ask... I'd hate to stop thinking of you as a friend," Zubov says.
In a brief but sinister post-credits scene, we get a pretty clear idea of what Zubov's intentions will be in future seasons. Zubov and his wife head to an esteemed-looking lunch spot, where they discover three older men waiting at their table. Fearing the worst from the influential members of the Klept, Dominika bids farewell to her husband and quickly vacates the area.
Additionally, the network along with showrunners will likely have to come to an agreement in regards to filming, writing, and more for a potential next season. Not to mention, Prime Video may want to consider how the series performs and analyze reviews before announcing another season.
The Peripheral Songs from the TV Serie Soundtrack 2022 Amazon Prime Video. Complete List of Songs, by episodes, with Music Samples, opening and closing credits and Trailer Songs. Listen to the Soundtrack.
Objective: To identify individuals at risk of developing ongoing dizziness 3 months after an acute peripheral vestibular disorder episode, which is usually functionally compensated or even healed within a few weeks.
Methods: In a prospective longitudinal study, we assessed fear of bodily sensations and cognitions related to anxiety at the time of hospital admission and 3 months later in 43 patients with an episode of vestibular neuritis (VN) or benign paroxysmal positional vertigo (BPPV). All participants were assessed for mental disorders using a structured clinical interview.
Results: Only the interaction between fear of bodily sensations within the first 2 weeks after admission and the type of vestibular disorder predicted the extent of dizzy complaints 3 months later; this accounts for 21% of the variance in a multiple regression analysis. Specifically, the prediction was valid only in patients with VN but not in patients with BPPV. Further analysis demonstrated that the interaction was not due to the peripheral vestibular disorder per se but rather determined by the initial severity of dizziness, which was significantly different in BPPV and VN patients.
Conclusions: The present study demonstrates that, for the development of persistent psychogenic dizziness after a peripheral vestibular disorder, the fear of bodily sensations is only relevant in interaction with the initial severity of dizziness experienced during the acute organic episode. To prevent development of persistent psychogenic dizziness, we feel that our results indicate the need to screen patients with vestibular disorders for at-risk status and offer them psychological support to deal with their symptoms.
The aim of this study was to evaluate the efficacy and safety of high-dose taurine supplementation for prevention of stroke-like episodes of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes), a rare genetic disorder caused by point mutations in the mitochondrial DNA that lead to a taurine modification defect at the first anticodon nucleotide of mitochondrial tRNALeu(UUR), resulting in failure to decode codons accurately.
The proportion of patients who reached the primary endpoint (100% responder rate) was 60% (95% CI 26.2% to 87.8%). The 50% responder rate, that is, the number of patients achieving a 50% or greater reduction in frequency of stroke-like episodes, was 80% (95% CI 44.4% to 97.5%). Taurine reduced the annual relapse rate of stroke-like episodes from 2.22 to 0.72 (P=0.001). Five patients showed a significant increase in the taurine modification of mitochondrial tRNALeu(UUR) from peripheral blood leukocytes (P
The current study demonstrates that oral taurine supplementation can effectively reduce the recurrence of stroke-like episodes and increase taurine modification in mitochondrial tRNALeu(UUR) in MELAS.
Following a nationwide survey of MELAS across Japan, we conducted a multicentre, open-label, phase III trial to evaluate the efficacy and safety of high-dose taurine supplementation for prevention of stroke-like episodes. We further investigated the molecular effect of taurine supplementation by determining taurine modification in mitochondrial tRNALeu(UUR) from peripheral blood leucocytes of participants in the trial.
We defined stroke-like episodes of MELAS in the inclusion criteria as focal neurological deficits with abrupt onset, including (1) hemiparesis or monoparesis, (2) cortical sensory deficit (extinction), (3) cortical visual deficit, (4) aphasia, (5) apraxia and (6) agnosia. At the time of registration, brain MRI was not mandatory in order to avoid underestimation of the frequency of stroke-like episodes during the pretrial period. Based on the data from the nationwide survey, we selected participants who had frequent recurrence of stroke-like episodes; more than twice within the last 78 weeks and at least once within the last 52 weeks before the date of enrolment.
Taurine was administered for 52 weeks of the trial period and the first 8 weeks after the taurine administration were not included in the evaluation period (figure 2). Stroke-like episodes observed during the evaluation period were precisely defined as abrupt-onset focal neurological deficits confirmed by brain MRI abnormalities.
The primary endpoint was the 100% responder rate, defined as the percentage of patients with no stroke-like episodes during the trial period. The secondary endpoints included the following: (1) the 50% responder rate defined as the percentage of patients achieving 50% or greater reduction in frequency of stroke-like episodes during the trial period; (2) the number of attacks with focal neurological deficits with or without brain MRI abnormalities; (3) the levels of lactate, pyruvate and taurine in blood and cerebrospinal fluid (CSF); (4) the number of times high-intensity lesions were confirmed with brain MRI in patients suffering from headache, nausea, vomiting, seizure or impaired consciousness; (5) the frequency of intravenous treatment with L-arginine24 before or after taurine administration, and (6) the disease severity index in accordance with the Japanese Mitochondrial Disease Rating Scale,6 which was modified from the European Neuromuscular Conference mitochondrial disease scale.26 041b061a72
